Barclays PLC Takes $215,000 Position in Electromed, Inc. (NYSE:ELMD)

Barclays PLC bought a new stake in shares of Electromed, Inc. (NYSE:ELMD - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 10,022 shares of the company's stock, valued at approximately $215,000. Barclays PLC owned approximately 0.12% of Electromed at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Renaissance Technologies LLC grew its position in Electromed by 4.8% during the second quarter. Renaissance Technologies LLC now owns 103,004 shares of the company's stock valued at $1,548,000 after purchasing an additional 4,736 shares in the last quarter. Hunter Associates Investment Management LLC grew its holdings in shares of Electromed by 12.3% during the 3rd quarter. Hunter Associates Investment Management LLC now owns 102,450 shares of the company's stock valued at $2,199,000 after acquiring an additional 11,250 shares in the last quarter. Gabelli Funds LLC raised its holdings in shares of Electromed by 7.8% during the second quarter. Gabelli Funds LLC now owns 38,675 shares of the company's stock worth $581,000 after acquiring an additional 2,808 shares in the last quarter. Pekin Hardy Strauss Inc. boosted its position in Electromed by 9.9% during the third quarter. Pekin Hardy Strauss Inc. now owns 38,185 shares of the company's stock valued at $820,000 after purchasing an additional 3,435 shares during the last quarter. Finally, State Street Corp boosted its position in Electromed by 14.5% during the third quarter. State Street Corp now owns 22,066 shares of the company's stock valued at $474,000 after purchasing an additional 2,800 shares during the last quarter. Institutional investors and hedge funds own 40.82% of the company's stock.

Analyst Ratings Changes

Separately, StockNews.com downgraded Electromed from a "strong-buy" rating to a "buy" rating in a research note on Thursday, January 9th.

Electromed Stock Down 1.2 %

ELMD stock traded down $0.39 during trading hours on Wednesday, hitting $33.51. The company's stock had a trading volume of 64,506 shares, compared to its average volume of 96,354. The stock has a 50 day moving average price of $29.72 and a two-hundred day moving average price of $22.46. Electromed, Inc. has a 12 month low of $9.90 and a 12 month high of $35.07. The company has a market capitalization of $283.49 million, a PE ratio of 46.54 and a beta of 0.31.

Electromed (NYSE:ELMD - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.13. The company had revenue of $14.67 million for the quarter. Electromed had a return on equity of 15.32% and a net margin of 11.34%.

Insiders Place Their Bets

In related news, Director Andrew Summers sold 17,463 shares of the company's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $30.09, for a total transaction of $525,461.67. Following the completion of the transaction, the director now directly owns 189,838 shares in the company, valued at $5,712,225.42. This represents a 8.42 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 14.00% of the company's stock.

Electromed Company Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.